Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Edwards’ Sapien 3 With The Alterra Prestent For Pulmonary Regurgitation

Executive Summary

The new device combines Edwards’ market-leading Sapien 3 transcatheter heart valve with its Alterra adaptive prestent device to treat patients with severe pulmonary regurgitation due to congenital valve defects.

You may also be interested in...



Edwards Stays On Track For ‘Mid-Teens’ TAVR Growth In 2021

Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.

FDA Approves Two New Indications For Edwards’ Sapien 3 TAVR System

Sapien 3 is now indicated to treat failed right ventricular outflow tract conduits, surgical bioprosthetic pulmonary valves and transcatheter aortic valves.

JPM 2022: Abiomed, Penumbra, Renalityx

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel